Prostate Cancer - Results from #1700

Phenotype plasticity and altered sensitivity to chemotherapeutic agents in aggressive prostate cancer cells. December 5, 2023

Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer. December 4, 2023

Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. December 4, 2023

Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men. December 4, 2023

Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients. December 4, 2023

Comparison of Urinary Diversion in Patients with Prostatic Fistula to Those with Localized Radiation Injury after Radiotherapy for the Treatment of Prostate Cancer. December 4, 2023

Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer. December 4, 2023

UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance. December 4, 2023

Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells. December 4, 2023

First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level December 1, 2023

Registrational Phase III CLARIFY Trial in Prostate Cancer Commences December 1, 2023

Clinical outcomes for men with positive surgical margins after radical prostatectomy-results from the South Australian Prostate Cancer Clinical Outcomes Collaborative community-based registry. December 1, 2023

Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial. December 1, 2023

Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. December 1, 2023

Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617. December 1, 2023

CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer. December 1, 2023

Social Drivers of Cancer Risk and Outcomes Among African American Men. December 1, 2023

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer. December 1, 2023

POSTER: Phase 1/2 Trial of Oral EPI-7386 (masofaniten) in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects mCRPC: Current Phase 1 (P1) Results November 30, 2023

Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis. November 30, 2023

Page 86 of 1435